Home › Acute myeloïde leukemie › South Carolina › Greenville
Acute myeloïde leukemie klinische studies in Greenville, SC
10 studies voor Acute myeloïde leukemie zoeken deelnemers op locaties in en rond Greenville (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RekruterenFase 2
- Prisma Health Cancer Institute - Butternut, Greenville
- Prisma Health Cancer Institute - Faris, Greenville
- Prisma Health Cancer Institute - Eastside, Greenville
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruterenObservatieonderzoekGezonde vrijwilligers welkom
- Prisma Health Cancer Institute - Faris, Greenville
- Prisma Health Greenville Memorial Hospital, Greenville
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
RekruterenFase 2
- Prisma Health Cancer Institute - Butternut, Greenville
- Prisma Health Cancer Institute - Faris, Greenville
- Prisma Health Cancer Institute - Eastside, Greenville
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
RekruterenFase 2
- Prisma Health Cancer Institute - Butternut, Greenville
- Prisma Health Cancer Institute - Faris, Greenville
- Prisma Health Cancer Institute - Eastside, Greenville
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RekruterenFase 2
- Prisma Health Cancer Institute - Butternut, Greenville
- Prisma Health Cancer Institute - Faris, Greenville
- Prisma Health Cancer Institute - Eastside, Greenville
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
RekruterenFase 2
- Prisma Health Cancer Institute - Butternut, Greenville
- Prisma Health Cancer Institute - Faris, Greenville
- Prisma Health Cancer Institute - Eastside, Greenville
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
RekruterenFase 3
- BI-LO Charities Children's Cancer Center, Greenville
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
RekruterenFase 1/2
- Bon Secours St. Francis Cancer Center, Greenville
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RekruterenFase 1/2
- BI-LO Charities Children's Cancer Center, Greenville
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RekruterenFase 1
- Prisma Health, Greenville
Acute myeloïde leukemie studies in andere steden
- Houston, TX85 studies
- New York City, NY51 studies
- Boston, MA44 studies
- Seattle, WA41 studies
- Baldwin Park, CA40 studies
- Columbus, OH35 studies
- Philadelphia, PA34 studies
- Durham, NC33 studies
- Atlanta, GA31 studies
- Tampa, FL29 studies
- Chicago, IL26 studies
- Portland, OR25 studies
Andere studies in Greenville
- Niet-kleincellige longkanker15 studies
- Borstkanker12 studies
- Kanker (alle vormen)9 studies
- Obesitas9 studies
- Longkanker9 studies
- Overgewicht8 studies
- Prostaatkanker7 studies
- Colorectale kanker7 studies
- Maagkanker6 studies
- Perifere arteriële ziekte5 studies
- Burkitt-lymfoom5 studies
- Melanoom5 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.